Artemis Hospitals
| インド | トルコ | オーストリア | |
| 血漿交換術 | から $4,200 | から $1,200 | から $2,000 |
| 血漿交換 | から $3,800 | から $3,900 | - |
| 治療的アフェレーシス | から $850 | から $1,350 | - |
| カスケードプラズマろ過 | から $1,350 | から $1,850 | - |
Bookimedは骨髄腫治療価格に追加料金を加算しません。料金はクリニックの公式価格表から来ています。国に到着時にクリニックで治療代を直接お支払いいただきます。
Bookimedはお客様の安全に取り組んでいます。骨髄腫治療で高い国際基準を維持し、世界中の国際患者サービスに必要なライセンスを有する医療機関とのみ協力しています。
Bookimedは無料専門サポートを提供します。専属医療コーディネーターが治療前、治療中、治療後にサポートし、あらゆる問題を解決します。骨髄腫治療の旅路でお一人になることはありません。
医師は、HCG Manavata Cancer Centre, Nashikで13年以上の経験を持つ非常に経験豊富な血液腫瘍学者であり、白血病、多発性骨髄腫、骨髄移植において専門知識を持っています。 <\/p>
Grant Medical CollegeおよびSir JJ HospitalでMBBSの学位を取得した後、医師はLokmanya Tilak Municipal Medical College, SionおよびMumbaiで病理学のMDを追求しました。 <\/p>
さらに、医師はMedical College, Calcuttaで臨床血液学のDMを取得し、プロフェッショナリズムと勤勉さで賞を受け、熟練した有能な専門家としての評判を強調しています。<\/p>
医師は放射線腫瘍学のMDを取得しており、コンサルタントとして勤務しています。進んだがん治療技術を専門とし、医師はトモセラピー-H、リニアアクセラレーター、ブラキセラピーを含むサービスを提供しています。これらのモダリティは、周囲の健康な組織への損傷を最小限に抑え、治療効果を高めるために正確な放射線治療を提供するために使用されます。<\/p>
Multiple myeloma is technically categorized as a chronic condition rather than permanently curable. Modern Indian oncology centers achieve deep, long-term remission using advanced therapies. JCI-accredited facilities offer autologous stem cell transplants and quadruplet drug protocols. These methods focus on controlling the disease for a decade or more.
Bookimed Expert Insight: While India is often selected for its low-cost care, the real advantage is the specialization depth in its largest hubs. For example, Global Hospital Chennai is part of a network serving 2,000,000 patients annually and performs over 18,000 procedures. This massive volume means specialists like Dr. Girish Badarkhe at HCG Manavata manage a highly diverse range of myeloma subtypes. High-volume centers often have better access to trials for bispecific antibodies and CAR-T therapies that are not yet widely commercialized.
Patient Consensus: Patients emphasize that `remission` is the realistic goal and warns that treatment is a marathon, not a sprint. Many note that outcomes improve significantly when choosing a dedicated hematology-oncology specialist rather than a general oncologist.
First-line myeloma treatment in Indian hospitals combines proteasome inhibitors with immunotherapy and stem cell transplants. Centers in Delhi and Bengaluru follow National Cancer Grid protocols. These focus on bortezomib-based triplets. Facilities often hold JCI and NABH accreditations to ensure international safety standards.
Bookimed Expert Insight: India is home to the first indigenous CAR T-cell therapy, NexCAR19. While traditional triplets are standard, hospitals like HCG Manavata and Global Hospital Chennai offer deep expertise in managing complex hematology. Dr. Girish Badarkhe at HCG Manavata alone holds significant experience in leukemia and myeloma. Patients should check if their facility utilizes IBM Watson for oncology to further refine drug selection based on genetic data.
Patient Consensus: Patients emphasize that doctors carefully adjust drug combinations based on kidney health and budget. They note it is important to confirm early if the treatment plan leads toward a stem cell transplant.
Active pharmaceutical ingredients for cancer drugs in India are identical to those in the US and Europe. Indian facilities manufacture 40% of US generics. Clinics use the same compounds like bortezomib and lenalidomide within Joint Commission International-accredited hospitals to ensure global safety standards.
Bookimed Expert Insight: India serves as a global manufacturing hub for complex oncology medications. Large networks like Manipal Hospitals and Apollo Hospitals serve over 1,000,000 patients annually. These facilities often implement the same drug protocols for myeloma as Western centers. Hospitals like HCG Manavata Cancer Centre even use technologies like Tomotherapy-H to complement these medications.
Patient Consensus: Patients note that while drug names change, the molecules remain consistent. Many emphasize that treatment success depends heavily on the oncologist’s experience at high-volume centers.
Myeloma treatment in India typically spans 3 to 12 weeks for international patients. Initial workups often begin within days of arrival. Stem cell transplants require the longest stay. High-volume centers like Apollo Hospitals or Manipal Hospitals expedite staging for visiting patients.
Bookimed Expert Insight: Patients arriving at large networks like Manipal Hospitals often bypass diagnostic delays common in smaller clinics. With over 1,900 doctors and 15 locations, these centers use coordinated hematology teams to finalize treatment plans in under 48 hours. This efficiency is critical for myeloma patients who require immediate induction therapy to manage bone pain or kidney issues.
Patient Consensus: Patients note that Indian hospitals frequently repeat baseline laboratory tests even if prior results are provided. It is important to factor in extra days for verify pathology and secure a second hematology opinion before starting intensive cycles.
Indian hospitals support international medical tourists through comprehensive international patient departments. These divisions provide visa invitation letters, remote video consultations, and detailed treatment plans. Facilities like Apollo Hospital Indraprastha and Manipal Hospitals handle over 1,000,000 international patients annually with dedicated logistics teams.
Bookimed Expert Insight: Data shows that India’s largest networks like Manipal and Apollo serve millions of patients because they operate as health systems, not just single buildings. For complex conditions like myeloma, choosing a facility with over 300+ doctors across 40 specialties, such as Artemis Hospitals, ensures that oncology, hematology, and infectious disease teams are integrated into one coordinated international care plan.
Patient Consensus: Patients emphasize that major private hospitals operate like a managed pipeline. They note that having a single coordinator for imaging, labs, and pharmacy helps minimize time away from home during intensive treatment cycles.